Recent advances in management of patients with platinum-refractory testicular germ cell tumors

Cancer

Volumn 106, Issue 6, 2006, Pages 1217-1226

  Kollmannsberger, Christian ^a,d   Nichols, Craig ^b   Bokemeyer, Carsten ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; AMSACRINE; BENDAMUSTINE; BLEOMYCIN; CISPLATIN; DACTINOMYCIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IMATINIB; IPROPLATIN; IRINOTECAN; MITOMYCIN C; MITOXANTRONE; NAVELBINE; NEDAPLATIN; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; RETINOIC ACID; SURAMIN; TEMOZOLOMIDE; TOPOTECAN; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

APOPTOSIS; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CLINICAL TRIAL; CROSS RESISTANCE; DNA DAMAGE; DRUG DESIGN; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; FEVER; GERM CELL TUMOR; HUMAN; METASTASIS; MONOTHERAPY; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SALVAGE THERAPY; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR RESISTANCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GERM CELL AND EMBRYONAL; ORGANOPLATINUM COMPOUNDS; SALVAGE THERAPY; TESTICULAR NEOPLASMS;

EID: 33644842476     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21742     Document Type: Review

References (85)

1. Einhorn LH. Treatment of testicular cancer: A new and improved model. J Clin Oncol. 1990;8:1777-1781.
2. Nichols CR, Roth BJ, Loehrer PJ, Williams SD, Einhorn LH. Salvage chemotherapy for recurrent germ cell cancer. Semin Oncol. 1994;5(suppl 12):102-108.
3. Rick O, Siegert W, Beyer J. Chemotherapy in patients with metastatic or relapsed germ-cell tumours. Cancer Treat Rev. 2001;27:283-288.
4. Nichols CR, Maziarz R. High-dose chemotherapy-treatment results in the USA. Int J Cancer. 1999;83:841-843.
5. Beyer J, Kramar A, Mandanas R, et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol. 1996; 14:2638-2645.
6. Porcu P, Bhatia S, Einhorn LH. Results of treatment after relapse from high-dose chemotherapy in germ cell tumors. J Clin Oncol. 2000;18:1181-1186.
7. Nichols CR, Tricot G, Williams SD, et al. Dose-intensive chemotherapy in refractory germ cell cancer - a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol. 1989;7:932-939.
8. Miller JC, Einhorn LH. Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol. 1990;17:36-39.
9. Masters JR, Koberle B. Curing metastatic cancer: lessons from testicular germ-cell tumours. Nat Rev Cancer. 2003;3:517-525.
10. Mayer F, Honecker F, Looijenga LH, Bokemeyer C. Towards an understanding of the biological basis of response to cisplatin-based chemotherapy in germ-cell tumors. Ann Oncol. 2003;14:825-832.
11. Niedner H, Christen R, Lin X, Kondo A, Howell SB. Identification of genes that mediate sensitivity to cisplatin. Mol Pharmacol. 2001;60:1153-1160. Review.
12. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000;92:1295-1302. Review.
13. Masters JR, Thomas R, Hall AG, et al. Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways. Eur J Cancer. 1996;32A:1248-1253.
14. Sark MW, Timmer-Bosscha H, Meijer C, et al. Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines. Br J Cancer. 1995; 71:684-690.
15. Scheffer GL, Kool M, Heijn M, et al. Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res. 2000;60:5269-5277.
16. Koberle B, Grimaldi KA, Sunters A, Hartley JA, Kelland LR, Masters JR. DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int J Cancer. 1997;70:551-555.
17. Koberle B, Masters JR, Hartley JA, Wood RD. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol. 1999;9:273-276.
18. Lutzker SG, Mathew R, Taller DR. A p53 dose-response relationship for sensitivity to DNA damage in isogenic teratocarcinoma cells. Oncogene. 2001;20:2982-2986.
19. Kersemaekers AM, Mayer F, Molier M, et al. Role of P53 and MDM2 in treatment response of human germ cell tumors. J Clin Oncol. 2002;20:1551-1561.
20. Burger H, Nooter K, Boersma AW, et al. Distinct p53-independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines. Int J Cancer. 1999;81:620-628.
21. Mayer F, Gillis AJ, Dinjens W, Oosterhuis JW, Bokemeyer C, Looijenga LH. Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment. Cancer Res 2002;62:2758-2760.
22. Mayer F, Stoop H, Scheffer GL, et al. Molecular determinants of treatment response in human germ cell tumors. Clin Cancer Res. 2003;9:767-773.
23. Williams SD, Birch R, Gams R, Irwin L. Phase II trial of mitoxantrone in refractory germ cell tumors: a trial of the Southeastern Cancer Study Group. Cancer Treat Rep. 1985; 69:1455-1456.
24. Harstrick A, Schmoll HJ, Wilke H, et al. High dose epirubicin in refractory or relapsed non-seminomatous testicular cancer: a phase II study. Ann Oncol. 1990;1:375-376.
25. Stoter G, Akdas A, Fossa SD, et al. High-dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer: A phase II study. Ann Oncol. 1992;3:577-578.
26. Hoskins P, Coppin CM, Murray N. Mitomycin is active against refractory germ-cell tumors. A phase II study. Am J Clin Oncol 1990;13:35-38.
27. Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs. 1996;7:415-421.
28. Kollmannsberger C, Gerl A, Schleucher N, et al. Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer. Anticancer Drugs. 2000;11:535-539.
29. Berney DM, Shamash J, Gaffney J, Jordan S, Oliver RT. DNA topoisomerase I and II expression in drug resistant germ cell tumours. Br J Cancer. 2002;87:624-629.
30. Puc HS, Bajorin D, Bosl GJ, Amsterdam A, Motzer RJ. Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors. Invest New Drugs. 1995;13:163-165.
31. Miki T, Sawada M, Nonomura N, et al. Antitumor effect of CPT-11, a camptothecin derivative, on human testicular tumor xenografts in nude mice. Eur Urol. 1997;31:92-96.
32. Kollmannsberger C, Rick O, Klaproth H, et al. Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group. Br J Cancer. 2002;87:729-732.
33. Pera MF, Koberle B, Masters JR. Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide. Br J Cancer. 1995;71:904-906.
34. Varuni Kondagunta G, Bacik J, Schwartz L, et al. Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors. Invest New Drugs. 2004;22:177-179.
35. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst. 1994;86:1517-1524.
36. Motzer RJ, Bajorin D, Schwartz LH, et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol. 1994;12:2277-2283.
37. Bokemeyer C, Beyer J, Metzner B, et al. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol. 1996;7:31-34.
38. Bokemeyer C, Hartmann JT, Kuczyk MA, et al. The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tumors. World J Urol. 1996;14:354-359.
39. Motzer RJ, Mazumdar M, Sheinfeld J, et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol. 2000;18:1173-1180.
40. Bokemeyer C, Gerl A, Schoffski P, et al. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol. 1999;17:512-516.
41. Einhorn LH, Stender MJ, Williams SD. Phase II trial of gemcitabine in refractory germ cell tumors. J Clin Oncol. 1999; 17:509-511.
42. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 1996;56:4881-4886.
43. Dunn TA, Schmoll HJ, Grunwald V, Bokemeyer C, Casper J. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell lines. Invest New Drugs. 1997; 15:109-114.
44. Soulie P, Garrino C, Bensmaine MA, et al. Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients. J Cancer Res Clin Oncol. 1999;125:707-711.
45. Kollmannsberger C, Rick O, Derigs HG, et al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol. 2002;20:2031-2037.
46. Raymond E, Lawrence R, Izbicka E, Faivre S, Von Hoff DD. Activity of oxaliplatin against human tumor colony-forming units. Clin Cancer Res. 1998;4:1021-1029.
47. Hinton S, Catalano PJ, Einhorn L, Kuzel T, Vaughn DJ, Wilding G. Phase II trial of paclitaxel and gemcitabine in refractory germ cell tumors. J Clin Oncol. 2001;20:1859-1863.
48. Faivre S, Raymond E, Woynarowski JM, Cvitkovic E. Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol. 1999;44:117-123.
49. Kollmannsberger C, Beyer J, Liersch R, et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: A study of the German Testicular Cancer Study Group. J Clin Oncol. 2004;22:108-114.
50. Pectasides D, Pectasides M, Farmakis D, et al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol. 2004;15:493-497.
51. Theodore C, Flechon A, Fizazi K, et al. A phase II multicenter study of oxaliplatin (Ox) in combination with paclitaxel (Px) in patients (pts) who failed cisplatin (CDDP) based chemotherapy (CT) for germ cell tumors (GCT) [abstract]. Proc Am Soc Clin Oncol. 2004;23:389. Abstract 4534.
52. Miki T, Mizutani Y, Nonomura N, et al. Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors. Cancer. 2002;95:1879-1885.
53. Kano Y, Suzuki K, Akutsu M, et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer. 1992;50:604-610.
54. Zeghari-Squalli N, Raymond E, Cvitkovic E, Goldwasser F. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res. 1999;5:1189-1196.
55. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol. 1998;25(2 suppl 5):4-12. Review.
56. Pectasides D, Pectasides M, Farmakis D, et al. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study. Eur Urol. 2004; 46:216-221.
57. Murphy BR, Breeden ES, Donohue JP, et al. Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol. 1993;11:324-329.
58. Eastham JA, Wilson TG, Russell C, Ahlering TE, Skinner DG. Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. Urology. 1994;43:74-80.
59. Coogan CL, Foster RS, Rowland RG, et al. Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone. Urology. 1997;50:957-962.
60. Albers P, Ganz A, Hannig E, Miersch WD, Muller SC. Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol. 2000;164:381-384.
61. George DW, Foster RS, Hromas RA, et al. Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol. 2003;21:113-122.
62. Gerl A, Clemm C, Schmeller N, Hentrich M, Lamerz R, Wilmanns W. Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol. 1997;8:41-47.
63. Dieckmann KP, Albers P, Classen J, et al. Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases. J Urol. 2005;173:824-829.
64. Motzer RJ, Dmitrovsky E, Miller WH Jr, et al. Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial. Cancer. 1993;72:3313-3317.
65. Moasser MM, Motzer RJ, Khoo KS, et al. all-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial. Cancer. 1995;76:680-686.
66. Fukuda S, Shirahama T, Imazono Y, et al. Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease. Cancer. 1999;85:1323-1330.
67. Viglietto G, Romano A, Maglione D, et al. Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor. Oncogene. 1996;13:577-587.
68. Kollmannsberger C, Mayer F, Pressler H, et al. Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer. Cancer. 2002;95:301-308.
69. Kemmer K, Corless CL, Fletcher JA, et al. KIT mutations are common in testicular seminomas. Am J Pathol. 2004;164:305-313.
70. Tian Q, Frierson HF Jr, Krystal GW, Moskaluk CA. Activating c-kit gene mutations in human germ cell tumors. Am J Pathol. 1999;154:1643-1647.
71. Madani A, Kemmer K, Sweeney C, et al. Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors. Ann Oncol. 2003;14:873-880.
72. Moroni M, Veronese S, Schiavo R, et al. Epidermal growth factor receptor expression and activation in nonseminomatous germ cell tumors. Clin Cancer Res. 2001;7:2770-2775.
73. Soule S, Baldridge L, Kirkpatrick K, et al. HER-2/neu expression in germ cell tumours. J Clin Pathol. 2002;55:656-658.
74. Lock RB. TCL1: a new drug target in lymphoid and germ-cell malignancies? Int J Biochem Cell Biol. 2003;35:1614-168. Review.
75. Sonneveld DJ, Hoekstra HJ, van der Graff WT, et al. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer. 2001;91:1304-1315.
76. Farmakis D, Pectasides D, Pectasides M, et al. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor (G-CSF) as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor (GCT) patients: a phase II study [abstract]. Proc Am Soc Clin Oncol. 2004;23:389. Abstract 4545.
77. Pizzocaro G, Nicolai N, Salvioni R, Gianni L. Paclitaxel, cisplatin and gemcitabine (TPG) third line therapy in metastatic germ cell tumors (GCT) of the testis [abstract]. Proc Am Soc Clin Oncol. 2001;20. Abstract 773. Available at: http://www.asco.org/ac/1,1003,_12-002627-00_18-0010-00_19-00773,00.asp
78. De Giorgi U, Rosti G, Papiani G, et al. Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with Cisplatin-refractory germ cell tumor: preliminary experience. Am J Clin Oncol. 2004;27:457-460.
79. Williams SD, Duncan P, Einhorn LH. Phase II study of AMSA in refractory testicular cancer. Cancer Treat Rep. 1983;67:309-310.
80. Drasga RE, Williams SD, Einhorn LH, Birch R. Phase II evaluation of iproplatin in refractory germ cell tumors: a Southeastern Cancer Study Group trial. Cancer Treat Rep. 1987;71:863-864.
81. Murphy BA, Motzer RJ, Bosl GJ. Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT. Invest New Drugs. 1992;10:327-330.
82. Bokemeyer C, Droz JP, Hanauske A, Schroder M, Queiber W, Schmoll HJ. Treatment of relapsed nonseminomatous germ cell tumors with vinorelbine: a trial of the phase I/II study group of the Association of Medical Oncology of the German Cancer Society. Onkologie. 1993;16:29-31.
83. Bokemeyer C, Schmoll HJ, Natt F, Knoche M, Beyer J, Souchon R. Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. J Cancer Res Clin Oncol. 1994;120:754-757.
84. Nazario A, Amato RJ, Hutchinson L, Bui C, Ellerhorst J, Logothetis CJ. Paclitaxel in extensively pretreated nonseminomatous germ cell tumors. Urol Oncol. 1995;1:184-187.
85. Sandler AB, Cristou A, Fox S, et al. A phase II trial of paclitaxel in refractory germ cell tumors. Cancer. 1998;82:1381-1386.